Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new onset T1D a multicenter,randomized, double-blind, placebo-controlled trial
19/05/2022
Authors: Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, Luisa Daffonchio, Giovanni Goisis, Pier Adelchi Ruffini, Anna Rita Maurizi, Flavio Mantelli, Marcello Allegretti
Published in:
"DOM (Diabetes, Obesity and Metabolism)"